The FDA just cleared a maggot-based wound treatment from a Singapore startup

FDA records show that MEDIFLY Maggots, produced by Singapore-based Cuprina Pte. Ltd., received 510(k) clearance on June 12, 2026. The device is indicated for debridement of non-healing necrotic skin and soft-tissue wounds, including pressure ulcers, neuropathic foot ulcers, and non-healing traumatic or post-surgical wounds.

Second carcass-eating fly species cleared by FDA for maggot wound therapy

fda cleared maggotbased wound treatment singapore startup

Health & Medicine

Science & Environment

Business & Finance

MEDIFLY Maggots are substantially equivalent to the predicate device, Medical MaggotsTM, based on the information provided in this 510(k) Premarket Notification.

MEDIFLY Maggots are indicated for debridement of non-healing necrotic skin and soft tissue wounds, including pressure ulcers, neuropathic foot ulcers, and non-healing traumatic or post-surgical wounds.

Ltd. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MEDIFLY Maggots™, its medical-grade Lucilia cuprina larvae used in maggot debridement therapy (MDT).

This week, the Food and Drug Administration approved a second species of fly known for consuming carrion for use in maggot wound treatment, as announced by Cuprina Holdings, a company based in Singapore that has branded its new therapeutic larvae as MediFly Maggots.

The FDA just cleared a maggot-based wound treatment from a Singapore startup

💬Discussion